scholarly journals Acanthosis nigricans, hyperinsulinaemia and risk factors for cardiovascular disease

2000 ◽  
Vol 6 (2-3) ◽  
pp. 416-424
Author(s):  
A. Bener ◽  
G. G. Lestringant ◽  
B. L. Nyomba ◽  
P. Frossard ◽  
H. Saadi
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Glucose Tolerance ◽  
United Arab Emirates ◽  
Acanthosis Nigricans ◽  
Glucose Tolerance Test ◽  
Density Lipoprotein ◽  
Tolerance Test ◽  
Abnormal Glucose Tolerance ◽  
High Prevalence

We examined the association between acanthosis nigricans, hyperinsulinaemia and other risk factors for cardiovascular disease in patients from the United Arab Emirates. Height, weight and sitting blood pressure were recorded in 122 patients with acanthosis nigricans, and blood samples were obtained for measuring fasting cholesterol, high-density lipoprotein cholesterol, triglyceride and uric acid levels. In addition, a glucose tolerance test was performed and blood was sampled for insulin and glucose. Our results indicate that the patients with acanthosis nigricans had a high prevalence of abnormal glucose tolerance and hyperinsulinaemia. In addition, euglycaemic patients with hyperinsulinaemia had a cluster of risk factors for cardiovascular disease

Hyperinsulinism, neonatal obesity and placental immaturity in infants born to women with one abnormal glucose tolerance test value

1998 ◽  
Vol 26 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Ute M. Schäfer-Graf ◽  
Julie Dupak ◽  
Martin Vogel ◽  
Joachim W. Dudenhausen ◽  
Siri L. Kjos ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Abnormal Glucose Tolerance

Danazol induces resistance to both insulin and glucagon in young women

1992 ◽  
Vol 82 (2) ◽  
pp. 211-217 ◽  
Author(s):  
Raymond Bruce ◽  
Ian Godsland ◽  
John Stevenson ◽  
Maxeen Devenport ◽  
Fiona Borth ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Tolerance Test ◽  
Intravenous Glucose Tolerance Test ◽  
Glucose Response ◽  
Intravenous Glucose ◽  
Intravenous Glucose Tolerance ◽  
Glucagon Concentration

1. Danazol elevates plasma insulin, plasma glucagon and serum low-density lipoprotein concentrations and reduces the serum high-density lipoprotein concentration. 2. Associations between these disturbances were studied in 17 women receiving danazol therapy for endometriosis. Eleven women underwent intravenous glucose tolerance tests with measurement of plasma glucose, insulin, C-peptide and glucagon concentrations and modelling analysis of intravenous glucose tolerance test concentration profiles. Six women underwent glucagon sensitivity tests. Serum concentrations of lipids and lipoproteins were measured in all cases. 3. Danazol reduced the fasting plasma glucose and insulin concentrations, but markedly raised the fasting plasma glucagon concentration. The insulin and C-peptide responses to the intravenous glucose tolerance test were increased twofold and the net decrement in glucagon concentration was increased tenfold. The glucose response to the intravenous glucose tolerance test was unaffected. Insulin sensitivity was reduced by 55%. Both first-phase plasma insulin responsiveness and net first-phase pancreatic insulin secretion were increased; insulin half-life was prolonged. The glucose response to the glucagon sensitivity test was reduced on treatment. The calculated low-density lipoprotein cholesterol level rose by 20%, whereas high-density lipoprotein cholesterol level fell by 47%. None of these changes in serum lipoprotein levels correlated with changes in insulin metabolism. In general, metabolic changes normalized after 3 months. 4. Danazol increases the sensitivity of pancreatic insulin and glucagon secretion to glucose. Danazol-induced insulin and glucagon resistance could be due to receptor down-regulation resulting from hypersecretion of insulin and glucagon.

scholarly journals Admission hyperglycemia and abnormal glucose tolerance at discharge in patients with acute myocardial infarction and no previous history of diabetes mellitus

Medicina ◽  
2007 ◽  
Vol 43 (12) ◽  
pp. 935 ◽  
Author(s):  
Irena Milvidaitė ◽  
Rimvydas Šlapikas ◽  
Audronė Statkevičienė ◽  
Marija Babarskienė ◽  
Dalia Lukšienė ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Glucose Tolerance ◽  
Glucose Concentration ◽  
Glucose Tolerance Test ◽  
Previous History ◽  
Tolerance Test ◽  
Abnormal Glucose Tolerance ◽  
History Of

The objective of this study was to determine frequency of admission hyperglycemia and abnormal glucose tolerance at discharge in patients with acute myocardial infarction and no previous history of diabetes mellitus. Methods and results. Data on 1522 patients with acute myocardial infarction and no previous history of diabetes mellitus were analyzed. Before discharge from hospital, standardized oral glucose tolerance test was performed in 197 patients with admission hyperglycemia. Results. Admission hyperglycemia (≥6.1 mmol/L) was determined in half of the patients with acute myocardial infarction: glucose concentration of 6.1–6.99 mmol/L was in 21.5% and ≥7.0 mmol/L in 30.1% of the patients. By using glucose tolerance test, normal glucose metabolism was noted in 57.9% of the patients with admission hyperglycemia; abnormal glucose tolerance was diagnosed newly in more than one-third and glucose concentration of ≥11.1 mmol/L in 10.1% of the patients. Conclusions. Abnormal glucose tolerance is a frequent feature in nondiabetic patients with admission hyperglycemia during acute myocardial infarction, and glucose tolerance test should be considered in all patients with ischemic heart disease for early modification of this risk factor.

Sign in / Sign up

Export Citation Format

Share Document